Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT00790400
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Conditions: Tuberous Sclerosis Complex (TSC);   Lymphangioleiomyomatosis (LAM)
Interventions: Drug: Everolimus (RAD001);   Drug: Placebo

Indicates status has not been verified in more than two years